PMID: 9445007Jan 28, 1998Paper

A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines

Journal of Virology
T AraiH Iba

Abstract

We report here on stable prepackaging cell lines which can be converted into packaging cell lines for high-titer vesicular stomatitis virus G protein (VSV-G)-pseudotyped retrovirus vectors by the introduction of Cre recombinase-expressing adenovirus. The generated prepackaging cell lines constitutively express the gag-pol genes and contain an inducible transcriptional unit for the VSV-G gene. From this unit, the introduced Cre recombinase excised both a neomycin resistance (Neo(r)) gene and a poly(A) signal flanked by a tandem pair of loxP sequences and induced transcription of the VSV-G gene from the same promoter as had been used for Neo(r) expression. By inserting an mRNA-destabilizing signal into the 3' untranslated region of the Neo(r) gene to reduce the amount of Neo(r) transcript, we were able efficiently to select the clones capable of inducing VSV-G at high levels. Without the introduction of Cre recombinase, these cell lines produce neither VSV-G nor any detectable infectious virus at all, even after the transduction of a murine leukemia virus-based retrovirus vector encoding beta-galactosidase. They reproducibly produced high-titer virus stocks of VSV-G-pseudotyped retrovirus (1.0 x 10(6) infectious units/ml) from 3 ...Continue Reading

References

Dec 1, 1987·Journal of Virology·K T FujiwaraS Kawai
Aug 1, 1987·Molecular and Cellular Biology·C Chen, H Okayama
Aug 25, 1995·Science·E Marshall
Jun 1, 1994·Japanese Journal of Medical Science & Biology·Y KanegaeI Saito
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·J K YeeT Friedmann
Aug 1, 1996·Journal of Virology·A P RussH von Melchner
Aug 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·K A Westerman, P Leboulch
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·D S OryR C Mulligan
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·A D Miller

❮ Previous
Next ❯

Citations

Jul 26, 2000·Development, Growth & Differentiation·H Iba
Mar 10, 2001·Human Gene Therapy·B VogtD von Laer
Nov 22, 2005·Oncogene·J Michael MathisDavid T Curiel
Jun 1, 2006·Journal of Periodontology·Naohiko HasegawaHidemi Kurihara
Feb 7, 2009·Tissue Engineering. Part C, Methods·Brian KealyTimothy O'Brien
May 13, 2010·The Journal of Biological Chemistry·Toshio TandoHideo Iba
Mar 11, 2003·Reviews in Medical Virology·Hideo IbaTaiji Ito
Apr 7, 2005·Biotechnology and Bioengineering·María de las Mercedes SeguraAlain Garnier
Feb 19, 2002·The Journal of Biological Chemistry·Taketoshi MizutaniHideo Iba
Sep 30, 2010·Experimental Biology and Medicine·Anthony J BellArthur Bank
Feb 13, 2021·Viruses·Christopher Perry, Andrea C M E Rayat
Nov 10, 2000·Biochemical and Biophysical Research Communications·M UiH Iba
Aug 15, 1998·Biochemical and Biophysical Research Communications·M KanoM Masuda
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·D T Curiel
Aug 21, 2001·Biochemical and Biophysical Research Communications·S MizuaraiS Iijima
Jun 20, 2002·Journal of Virology·Simon J WalkerStephen Devereux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.